Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma

NCT00360854 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Brain and Central Nervous System Tumors

Interventions

DRUG: erlotinib hydrochloride
GENETIC: mutation analysis
GENETIC: polymorphism analysis
OTHER: laboratory biomarker analysis
OTHER: pharmacological study
RADIATION: radiation therapy

Sponsor

Children's Cancer and Leukaemia Group